排名前五的靶点	数量

ROR1(受体酪氨酸激酶样孤儿受体1)	1
IDH1(细胞质异柠檬酸脱氢酶[NADP])	1
PD-1(细胞程序性死亡-1)	1
PDL1(程序性死亡配体1)	1
ALK x ROS1	1

关联

项与基石药业相关的药物

Sugemalimab

舒格利单抗

靶点

PDL1

作用机制

PDL1抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-12-20

Pralsetinib

普拉替尼

靶点

RET

作用机制

RET抑制剂

在研机构

Hoffmann-La Roche Ltd. [+7]

原研机构

Blueprint Medicines Corp.

在研适应症

RET突变阳性甲状腺髓样癌 [+14]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-09-04

Avapritinib

阿伐替尼

靶点

PDGFRα x c-Kit

作用机制

PDGFRα抑制剂 [+1]

在研机构

Blueprint Medicines Corp. [+2]

原研机构

Blueprint Medicines Corp.

在研适应症

髓性系统性肥大细胞增多症 [+11]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-01-09

项与基石药业相关的临床试验

NCT05700448 / Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2024-11-01

申办/合作机构

基石药业（苏州）有限公司

CTR20232998 / CompletedN/A

评估受试制剂普拉替尼胶囊（规格：100 mg）与参比制剂普吉华®（规格：100 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复生物等效性研究

主要试验目的：研究空腹状态下单次口服受试制剂普拉替尼胶囊（规格：100 mg，凯莱英生命科学技术（天津）有限公司生产）与参比制剂普拉替尼胶囊（普吉华®，规格：100 mg；Catalent CTS, LLC生产）在健康受试者体内的药代动力学特征，评价空腹状态口服两种制剂的生物等效性。次要试验目的：研究受试制剂普拉替尼胶囊（规格：100 mg）和参比制剂普拉替尼胶囊（普吉华®）（规格：100 mg）在健康受试者中的安全性。

开始日期2023-10-30

申办/合作机构

基石药业（苏州）有限公司

CTR20231530 / CompletedN/A

评估受试制剂普拉替尼胶囊（规格：100 mg）与参比制剂普吉华®（规格：100 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、三周期、三序列、部分重复交叉生物等效性研究

主要试验目的：研究空腹状态下单次口服受试制剂普拉替尼胶囊（规格：100 mg）与参比制剂普拉替尼胶囊（普吉华®，规格：100 mg）在健康受试者体内的药代动力学特征，评价空腹状态口服两种制剂的生物等效性。次要试验目的：研究受试制剂普拉替尼胶囊（规格：100 mg）和参比制剂普拉替尼胶囊（普吉华®，规格：100 mg）在健康受试者中的安全性。

开始日期2023-06-13

申办/合作机构

基石药业（苏州）有限公司

100 项与基石药业相关的临床结果

登录后查看更多信息

0 项与基石药业相关的专利（医药）

登录后查看更多信息

项与基石药业相关的文献（医药）

2024-09-01·Targeted Oncology

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma

Article

作者: Zhang, Yanqiao ; Yue, Zenglian ; Wu, Rachel ; Guo, Ye ; Su, Rila ; Huang, Gang ; Wang, Ziping ; Zhou, Yuhong ; Gong, Jifang ; Wang, Mengzhao ; Tse, Archie N ; Yang, Haiyan ; Zhang, Wei ; Cai, Qiqing ; Li, Wei ; Dou, Jinzhou ; Chen, Tong ; Shen, Lin ; Zhou, Caicun ; Li, Peiqi ; Ba, Yi ; Cai, Zhongheng ; Tse, Archie N.

BACKGROUNDImmune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies has demonstrated efficacy in multiple tumor types. Nofazinlimab is a humanized rat antibody targeting PD-1. A first-in-human study of nofazinlimab conducted in Australia found no dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) was not reached in the range of 1-10 mg/kg.OBJECTIVEWe evaluated nofazinlimab for multiple advanced malignancies in Chinese patients.PATIENTS AND METHODSThis was a phase 1a/1b, open-label, multicenter, dose-escalation/expansion trial. In phase 1a, patients received an abbreviated dose escalation of nofazinlimab at 60 mg and 200 mg every 3 weeks (Q3W) to determine DLTs and the recommended phase 2 dose (RP2D). In phase 1b, patients received the RP2D (monotherapy/combination) in six arms by tumor type; DLTs were evaluated for nofazinlimab plus lenvatinib in the unresectable hepatocellular carcinoma (uHCC) arm. Safety (continuously monitored in patients who received nofazinlimab) and efficacy (patients with measurable baseline disease) were assessed.RESULTSOverall, 107 patients were eligible and received nofazinlimab. In phase 1a, no DLTs were observed; the RP2D was 200mg Q3W. In phase 1b, no DLTs were observed with nofazinlimab plus lenvatinib. The safety profile was consistent with that observed in the first-in-human study (NCT03475251). In phase 1b, 21/88 (23.9%) patients achieved confirmed objective responses, 26 (29.5%) had stable disease, and 9/20 (45.0%) patients with uHCC achieved confirmed objective responses to nofazinlimab plus lenvatinib.CONCLUSIONSNofazinlimab was well tolerated in Chinese patients. Preliminary efficacy was encouraging, particularly for nofazinlimab plus lenvatinib in uHCC, which is being studied in an ongoing phase 3 trial.CLINICAL TRIAL REGISTRATIONNCT03809767; registered 18 January 2019.

2024-06-01·Journal of Clinical Oncology

A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.

作者: Zhou, Caicun ; Wang, Jingru ; Shen, Zhenwei ; Zhou, Keshu ; Barve, Minal A. ; Song, Yuqin ; Zuniga, Richard ; Cherng, Hua-Jay Jeffery ; Zhu, Xiaoli ; Shen, Lin ; Yang, Jason ; Zhang, Jian ; Bishnoi, Sarwan ; Li, Fei ; Zhu, Dan ; Zhang, Liling ; Li, Wenyu ; Lemech, Charlotte Rose

3023 Background: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an embryonic tyrosine kinase-like molecule implicated in multiple pathways promoting oncogenic signaling. ROR1 is overexpressed in a broad spectrum of solid tumors and hematological malignancies while notably absent in normal tissues. CS5001 is an antibody drug conjugate (ADC) composed of a human anti–ROR1 IgG1 monoclonal antibody which is site-specifically conjugated to a pyrrolobenzodiazepine dimer prodrug through a proprietary lysosomal cleavable β-glucuronide linker. Here, we report preliminary phase 1a results of CS5001 in patients (pts) with advanced solid tumors and lymphomas. Methods: This is a global, first-in-human, phase 1a/b study evaluating the safety, pharmacokinetics (PK), and anti-tumor activity of CS5001 in pts with advanced solid tumors and lymphomas. CS5001 was administered intravenously Q3W with a 42-day-DLT period. In phase 1a (dose escalation), pts who had progressed on or been intolerant to standard therapies were enrolled without baseline ROR1 expression testing; accelerated titration followed by Bayesian Optimal Interval design was employed; in parallel with dose escalation, additional pts were enrolled to selected dose levels deemed safe to further evaluate safety and efficacy. Results: As of 15 Jan 2024, 49 pts with lymphomas (n=17) and solid tumors (n=32) were treated across 8 dose levels (7 to 125 μg/kg). Median age was 57 years. Most (n=40, 81.6%) pts had received ≥3 lines of prior anti-tumor treatment. No DLT was observed and MTD was not reached. Treatment-related adverse events (TRAEs) occurred in 29 pts (59.2%); the most common TRAE was fatigue (n=8, 16.3%). Grade 3 TRAEs occurred in 7 pts (14.3%), with fatigue, gamma-glutamyltransferase increased and pneumonia being the most common (occurring in 2 pts [4.1%] each). No grade 4-5 TRAEs were reported. Drug exposure of CS5001 was proportional to dose in general, with an apparent half-life of about 5 days. The PK profile of CS5001 was similar to that of total antibody, indicating good stability of the ADC in the circulation. Among the 34 pts with post baseline tumor assessment (13 lymphomas and 21 solid tumors), objective responses were observed in pts at dose level 5 or above (n=23), including 2 complete responses (1 Hodgkin lymphoma [HL] and 1 diffuse large B-cell lymphoma) and 3 partial responses (2 HL and 1 pancreatic cancer). Stable diseases were observed in 3 pts (2 colorectal cancer and 1 renal cancer). Dose escalation is still ongoing, and more data will be available at the conference presentation. Conclusions: CS5001 was well tolerated with no DLT identified, PK characteristics were as expected, and encouraging antitumor activities were observed in various advanced solid tumors and lymphomas. Current data support continued evaluations for the recommended phase 2 dose and subsequent phase 1b dose expansion. Clinical trial information: NCT05279300 .

2024-06-01·Cancer

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Article

作者: Su, Rila ; Moore, Maggie ; Yau, Thomas ; Ma, Yiding ; Li, Fei ; Prawira, Amy ; Aghmesheh, Morteza ; Eek, Richard ; Pan, Zhaoxuan ; Chan, Stephen L ; Li, Peiqi ; Mant, Andrew ; Zielinski, Robert ; Cosman, Rasha ; Bishnoi, Sarwan ; Kotasek, Dusan ; Tse, Archie N

AbstractBackgroundThis study investigated the safety and efficacy of an anti–CTLA‐4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti–PD‐1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid tumors.MethodsThe phase 1 study involved phase 1a monotherapy dose‐escalation (part 1) and phase 1b combination therapy dose escalation (part 2) and expansion (part 3). Various dosing schedules of CS1002 (0.3, 1, or 3 mg/kg every 3 weeks, or 3 mg/kg every 9 weeks) were evaluated with 200 mg CS1003 every 3 weeks in part 3.ResultsParts 1, 2, and 3 included a total of 13, 18, and 61 patients, respectively. No dose‐limiting toxicities or maximum tolerated doses were observed. Treatment‐related adverse events (TRAEs) were reported in 30.8%, 83.3%, and 75.0% of patients in parts 1, 2, and 3, respectively. Grade ≥3 TRAEs were experienced by 15.4%, 50.0%, and 18.3% of patients in each part. Of 61 patients evaluable for efficacy, 23 (37.7%) achieved objective responses in multiple tumor types. Higher objective response rates were observed with conventional and high‐dose CS1002 regimens (1 mg/kg every 3 weeks or 3 mg/kg every 9 weeks) compared to low‐dose CS1002 (0.3 mg/kg every 3 weeks) in microsatellite instability‐high/mismatch repair‐deficient tumors, melanoma, and hepatocellular carcinoma (50.0% vs. 58.8%, 14.3% vs. 42.9%, and 0% vs. 16.7%).ConclusionCS1002, as monotherapy, and in combination with CS1003, had a manageable safety profile across a broad dosing range. Promising antitumor activities were observed in patients with immune oncology (IO)‐naive and IO‐refractory tumors across CS1002 dose levels when combined with CS1003, supporting further evaluation of this treatment combination for solid tumors.Plain Language Summary

CS1002 is a human immunoglobulin (Ig) G1 monoclonal antibody that blocks the interaction of CTLA‐4 with its ligands and increases T‐cell activation/proliferation. CS1003, now named nofazinlimab, is a humanized, recombinant IgG4 monoclonal antibody that blocks the interaction between human PD‐1 and its ligands.

In this original article, we determined the safety profile of CS1002 as monotherapy and in combination with CS1003. Furthermore, we explored the antitumor activity of the combination in anti–programmed cell death protein (ligand)‐1 (PD‐[L]1)‐naive microsatellite instability‐high/mismatch repair‐deficient (MSI‐H/dMMR) pan tumors, and anti–PD‐(L)1‐refractory melanoma and hepatocellular carcinoma (HCC).

CS1002 in combination with CS1003 had manageable safety profile across a broad dosing range and showed promising antitumor activities across CS1002 dose levels when combined with CS1003. This supports further assessment of CS1002 in combination with CS1003 for the treatment of solid tumors.

2,409

项与基石药业相关的新闻（医药）

2024-10-31

·PRNewswire

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the European Commission. The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with metastatic NSCLC. Long-term survival data from the GEMSTONE-302 study were presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. CStone is actively communicating with regulatory authorities, including the European Medicines Agency (EMA) for marketing authorization applications for additional indications of sugemalimab. CStone has entered into a strategic commercialization partnership with Ewopharma for sugemalimab in Central & Eastern Europe and Switzerland, with further collaborations expected soon in regions including Western Europe, Latin America, the Middle East, and Southeast Asia. SUZHOU, China, Oct. 31, 2024 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab in combination with platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) without EGFR-sensitive mutations or ALK, ROS1, RET genomic alterations. This marks the second overseas approval for sugemalimab following its recent authorization by the European Commission. Dr. Jason Yang, CEO, President of R&D and Executive Director of the Board at CStone, said, "This approval is a significant milestone in our global expansion strategy. Sugemalimab is the first domestic anti-PD-L1 antibody to receive approval outside of China and has already entered the world's second-largest pharmaceutical market, the EU. Now, with the UK approval, sugemalimab continued to expand its presence in the European market. The long-term survival data, recently presented at this year's ESMO Congress, further confirmed sugemalimab's value in the frontline treatment landscape for metastatic NSCLC." Dr. Yang added, "We are actively pursuing additional partnerships across Western Europe, Latin America, the Middle East, Southeast Asia, and Canada, and expect to finalize some of these agreements shortly. Meanwhile, we are communicating with the European Medicines Agency (EMA) and other agencies for additional regulatory applications for other sugemalimab indications, including Stage III NSCLC, first-line gastric cancer, and first-line esophageal squamous cell carcinoma, aiming to bring innovative treatment options to more patients globally." The MHRA's approval is primarily based on the data from GEMSTONE-302, a multicenter, randomized, double-blind phase 3 trial. The study demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to placebo combined with chemotherapy in treatment-naïve patients with metastatic NSCLC. Study results have been published in The Lancet Oncology and Nature Cancer, and have been presented at multiple international academic conferences in both oral and poster sessions. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准临床结果

2024-10-31

·Insight数据库

国产首个！基石药业 PD-L1 单抗「舒格利单抗」在英国获批

10 月 31 日，基石药业宣布，英国药品和医疗保健用品管理局（MHRA）已批准舒格利单抗联合含铂化疗用于无 EGFR 敏感突变, 或无 ALK, ROS1, RET 基因组肿或无 ALK, ROS1, RET 基因组肿瘤变异的转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。这也是国产 PD-L1 单抗首次在英国获批上市。舒格利单抗是首个成功出海的国产 PD-L1 单抗，此前已于今年 7 月获得欧盟委员会批准上市，本次在英国的获批是其在海外市场获得的第二项上市许可申请批准。此次获批主要是基于 III 期临床研究——GEMSTONE-302 的结果。GEMSTONE-302 研究是一项多中心、随机、双盲的Ⅲ期临床试验，旨在评估舒格利单抗联合含铂化疗对比安慰剂联合含铂化疗，一线治疗 IV 期 NSCLC 患者的有效性和安全性。该试验主要研究终点为研究者评估的疾病无进展生存期（PFS）。 2024 年欧洲肿瘤内科学会（ESMO）年会上公布的数据显示：截至数据截止日期（2023 年 5 月 15 日），479 名患者中，分别被随机分配至舒格利单抗联合含铂化疗组（320 人）和安慰剂联合含铂化疗组（159 人）。两组的中位随访时间分别为 43.5 个月和 43.0 个月。在意向治疗人群（ITT）中，舒格利单抗联合化疗组的中位 OS 为 25.2 个月，安慰剂联合化疗组为 16.9 个月，风险比（HR）0.68（95% CI, 0.54-0.85），两组的四年生存率分别为 32.1% 和 17.3%。在 ITT 中，舒格利单抗联合化疗组的中位 PFS 为 9.0 个月，安慰剂联合化疗组为 4.9 个月（HR=0.49）。在不同肿瘤组织学类型和 PD-L1 表达水平的患者亚组中，舒格利单抗联合化疗均展现出持续的 PFS 和 OS 获益。截至数据截止日期，58 例接受舒格利单抗超过 2 年的患者，中位 DoR 尚未达到，4 年生存率为 92.6%。基线有脑转移的患者，与安慰剂联合化疗相比，舒格利单抗联合化疗同样延长了 PFS（HR=0.31）和 OS（中位 OS：26 个月 vs 9 个月，HR=0.44），4 年生存率为 36.4%。安全性结果与先前报道的结果一致。在海外商业化和注册方面，基石药业还正积极与来自西欧、拉美、中东、东南亚、加拿大等地区的合作伙伴洽谈，预计近期将达成其中多项商业合作。同时，该公司还在积极与欧洲药品管理局（EMA）等国际监管机构沟通舒格利单抗其他适应症，如 III 期 NSCLC、一线胃癌、一线食管鳞癌的上市申请。封面来源：企业 Logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

临床3期上市批准临床结果

2024-10-31

·医药观澜

刚刚！基石药业宣布抗PD-L1单抗在英国获批，一线治疗非小细胞肺癌

▎药明康德内容团队编辑基石药业刚刚宣布，英国药品和医疗保健用品管理局（MHRA）已批准舒格利单抗联合含铂化疗用于无EGFR敏感突变, 或无ALK, ROS1, RET基因组肿瘤变异的转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。这是继欧盟委员会批准之后，舒格利单抗在国际市场获得的第二项上市许可申请的批准。此次获批主要是基于一项多中心、随机、双盲的3期临床研究——GEMSTONE-302的结果。舒格利单抗联合化疗对比安慰剂联合化疗，可显著延长初治转移性NSCLC患者的无进展生存期和总生存期。该研究数据已在《柳叶刀·肿瘤学》和《自然·癌症》上发表，并曾多次在国际学术会议上以口头汇报和壁报形式公布。基石药业首席执行官、研发总裁、执行董事杨建新博士在新闻稿中表示：舒格利单抗在英国获批，标志着公司全球化布局的又一重要里程碑。在今年ESMO上公布的长期生存数据，更是进一步巩固了舒格利单抗在转移性NSCLC一线治疗格局中的重要地位。他还表示，在国际商业化和注册方面，公司正积极与来自西欧、拉美、中东、东南亚、加拿大等地区的合作伙伴洽谈，预计近期将达成其中多项商业合作。同时，公司在积极与欧洲药品管理局（EMA）等国际监管机构沟通舒格利单抗其他适应症，如III期NSCLC、一线胃癌、一线食管鳞癌的上市申请，期待为全球更多患者带来创新的治疗方案。舒格利单抗是由基石药业研发的抗PD-L1单克隆抗体，其独特分子设计使其具备双重作用机制，不仅阻断PD-1/PD-L1相互作用，还能通过介导PD-L1表达阳性的肿瘤细胞与肿瘤相关巨噬细胞（TAMs），在诱导抗体依赖性细胞吞噬（ADCP）的同时不损害效应性T细胞。目前，中国国家药品监督管理局（NMPA）已批准舒格利单抗五项适应症：联合化疗一线治疗转移性鳞状和非鳞状NSCLC患者；治疗同步或序贯放化疗后未出现疾病进展的、不可切除、III期NSCLC患者；治疗复发或难治性结外NK/T细胞淋巴瘤患者；联合氟尿嘧啶类和铂类化疗药物一线治疗不可切除的局部晚期，复发或转移性食管鳞癌患者；联合含氟尿嘧啶类和铂类药物化疗用于表达PD-L1（综合阳性评分[CPS]≥5）的不可手术切除的局部晚期或转移性胃及胃食管结合部腺癌的一线治疗。在国际领域，欧盟委员会（EC）已批准舒格利单抗联合含铂化疗用于无EGFR敏感突变, 或无ALK, ROS1, RET基因组肿瘤变异的转移性NSCLC患者的一线治疗；英国药品和医疗保健用品管理局（MHRA）已批准舒格利单抗联合含铂化疗用于无EGFR敏感突变, 或无ALK, ROS1, RET基因组肿瘤变异的转移性NSCLC患者的一线治疗。参考资料： [1]国产PD-L1首度在英国获批！基石药业宣布舒格利单抗获英国药品和医疗保健用品管理局批准用于一线治疗非小细胞肺癌 Retrieved Oct 31，2024, from https://mp.weixin.qq.com/s/9F1906G2lFkf2ohU-Xm7qg 本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期上市批准临床结果申请上市医药出海

100 项与基石药业相关的药物交易

登录后查看更多信息

100 项与基石药业相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月17日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿伐替尼 ( PDGFRα x c-Kit )	PDGFRA D842V突变胃肠道间质瘤更多	批准上市
普拉替尼 ( RET )	RET融合阳性非小细胞肺癌更多	批准上市
艾伏尼布 ( IDH1 )	IDH1突变急性髓性白血病更多	批准上市
舒格利单抗 ( PDL1 )	胃食管交界处腺癌更多	批准上市
Nofazinlimab ( PD-1 )	晚期肝细胞癌更多	临床3期